Demonstration products and prices · Confirm all details with our team

Sexual Function and Reproductive Health性功能生殖

RT5 · 5mg ×10vials

5mg ×10vials

Retatrutide (LY3437943) is a first-in-class triple agonist peptide that simultaneously activates GLP-1, GIP, and glucagon receptors.

$125.00 USD

Select a variant

Prices are in USD per selected package. Confirm availability and final quotation with our team.

SKU
5mg ×10vials
Packaging
10 vials
Per-vial amount
5mg
Availability
Available for inquiry
Specifications
5mg*10vials
10mg*10vials
15mg*10vials
20mg*10vials
30mg*10vials
40mg*10vials
50mg*10vials
60mg*10vials
80mg*10vials
100mg*10vials
120mg*10vials
Intended use
For laboratory and in vitro research use only. Not for human use.
Ask about this product

For laboratory and in vitro research use only. Not for human use.

Product overview

Retatrutide (LY3437943) is a first-in-class triple agonist peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. Compared with dual agonists, this innovative triple-action mechanism may deliver greater weight-loss effects, increased energy expenditure, and enhanced hepatic fat oxidation.

In Phase II clinical trials, Retatrutide demonstrated an average weight reduction of 24.2% at 48 weeks. Phase III clinical trial TRIUMPH-4 reported average weight loss of approximately 28–29% at 68 weeks, alongside significant improvements in knee pain.

Additionally, Retatrutide has demonstrated promising benefits in reducing liver fat, lowering glycated hemoglobin (HbA1c) levels, and improving cardiovascular risk markers. Its reported adverse effects are primarily gastrointestinal in nature, similar to those associated with incretin-based therapies.

Retatrutide represents a new generation of advanced metabolic therapeutics.

This content is provided for research reference purposes only and should not be interpreted as health, clinical, or legal advice or guidance.

### **Benefits**

Supports appetite reduction and enhanced satiety; supports research into body weight and body fat reduction; improves blood glucose and insulin sensitivity markers; promotes energy expenditure and fat metabolism; may help improve lipid profiles and metabolic markers associated with fatty liver disease.

### **Usage Instructions**

For research or compliant clinical research use only. Typically administered via subcutaneous injection following reconstitution, by qualified professionals in accordance with an approved research protocol or medical guidance.

Dosage, dose escalation schedules, and treatment duration must be determined according to formal research protocols. A low starting dose followed by gradual titration is generally recommended in clinical research settings. Self-adjustment of dosage or prolonged use without appropriate supervision is not recommended.

Storage & handling

Unreconstituted lyophilized powder should be stored in a sealed container, protected from light, and kept at a low temperature. Long-term storage is generally recommended under refrigerated or frozen conditions, according to product specifications.
WhatsApp · Product support
LET’S TALK

Product support

Hello. Which product or specification would you like to learn about?

Selected product: RT5

Selected variant: 5mg ×10vials

Open WhatsApp

Review and confirm sending your message in WhatsApp.

Leave an inquiry for our team